Skin Cancer - Wesley Research Institute
Wesley Research Institute
Donate
Now

This project aims to find new biomarkers for immunotherapy in patients with melanoma.

Research Objectives

Status

Current

Study location

Wesley Research Insitute, The Wesley Hospital

Study Type

Industry Sponsored

About this clinical trial

Cancer immunotherapy has been shown to provide patients with an excellent new type of treatment and is in common use world-wide. Unfortunately, we know that not all patients will respond to their immunotherapy treatment in the same way.

Responses to immunotherapy may be affected by a patient’s microbiome, or the community of bacteria that live in their bowel. This group of bacteria can influence the immune system by increasing or decreasing certain types of white cells, called T cells that are produced in the body. By analysing the bacteria, this project aims to find new biomarkers for immunotherapy in patients with melanoma.

 

Finding new biomarkers for immunotherapy in patients with melanoma

Eligibility

Lead investigators

Technical title

Metabolomics in Enhancing Responses to Cancer ImmunoTherapy in Melanoma (MERIT-M)

Register your interest

If you would like more information about this clinical trial, please complete the contact form below.

Name
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram